Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22821915 | 0.77 | SMPD3 (0.41) | MAP4K4SMPD3ALDH1A1HTTKDM4E | |
| SCHEMBL22804172 | 0.77 | MAP4K4 (0.39) | MAP4K4SMPD3ALDH1A1HTTKDM4E | |
| SCHEMBL22821756 | 0.70 | SMPD3 (0.34) | MAP4K4SMPD3ALDH1A1HTTKDM4E | |
| SCHEMBL23392302 | 0.69 | ALDH1A1 (0.33) | MAP4K4ALDH1A1HTTKDM4EAKT1 | |
| SCHEMBL31291220 | 0.67 | MAP4K4 (0.36) | MAP4K4SMPD3ALDH1A1DYRK1A | |
| SCHEMBL31291221 | 0.67 | MAP4K4 (0.36) | MAP4K4SMPD3ALDH1A1DYRK1A | |
| SCHEMBL736971 | 0.65 | NUDT1 (0.50) | MAP4K4SMPD3ALDH1A1HTTKDM4E | |
| SCHEMBL17505371 | 0.63 | MAP4K4 (0.36) | MAP4K4SMPD3ALDH1A1HTTKDM4E | |
| Hydrochloric Acid SCHEMBL29445764 | 0.63 | HTT (0.38) | MAP4K4SMPD3ALDH1A1HTTKDM4E | |
| SCHEMBL15652300 | 0.61 | DYRK1A (0.33) | MAP4K4SMPD3ALDH1A1KDM4EAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-20220347175-A1 | PYRIDAZINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347175-A1 | PYRIDAZINONE DERIVATIVE | SCN1A, SCN1B, SCN3A | MAP4K4 970/4885SMPD3 840/4885ALDH1A1 1429/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | MAP4K4 902/4885SMPD3 814/4885ALDH1A1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.